Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
Nature Medicine · 2025-02 · 31 (2) · 457-465
DOI: 10.1038/s41591-024-03352-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 03.01.2025. Verfasst von Xavier Orcutt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Navajo Indian Health Service, Chinle, AZ, USA. Hauptthemen laut MEDLINE: Machine Learning, Neoplasms, Randomized Controlled Trials as Topic, Medical Oncology. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Randomized controlled trials (RCTs) evaluating anti-cancer agents often lack generalizability to real-world oncology patients. Although restrictive eligibility criteria contribute to this issue, the role of selection bias related to prognostic risk remains unclear. In this study, we developed TrialTranslator, a framework designed to systematically evaluate the generalizability of RCTs for oncology therapies. Using a nationwide database of electronic health records from Flatiron Health, this framework emulates RCTs across three prognostic phenotypes identified through machine learning models. We applied this approach to 11 landmark RCTs that investigated anti-cancer regimens considered standard of care for the four most prevalent advanced solid malignancies. Our analyses reveal that patients in low-risk and medium-risk phenotypes exhibit survival times and treatment-associated survival benefits similar to those observed in RCTs. In contrast, high-risk phenotypes show significantly lower survival times and treatment-associated survival benefits compared to RCTs. Our results were corroborated by a comprehensive robustness assessment, including examinations of specific patient subgroups, holdout validation and semi-synthetic data simulation. These findings suggest that the prognostic heterogeneity among real-world oncology patients plays a substantial role in the limited generalizability of RCT results. Machine learning frameworks may facilitate individual patient-level decision support and estimation of real-world treatment benefits to guide trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Navajo Indian Health Service, Chinle, AZ, USA.
- Department of Biostatistics, Harvard University, Boston, MA, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Penn Center for Cancer Care Innovation, Abramson Cancer Center, Philadelphia, PA, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. qlong@upenn.edu.
- Penn Center for Cancer Care Innovation, Abramson Cancer Center, Philadelphia, PA, USA. qlong@upenn.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Orcutt, X., Chen, K., Mamtani, R., Long, Q., & Parikh, R. B. (2025). Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nature Medicine, 31(2), 457-465. https://doi.org/10.1038/s41591-024-03352-5
Vancouver
Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nature Medicine. 2025;31(2):457-465. doi:10.1038/s41591-024-03352-5
BibTeX
@article{Orcutt2025,
author = {Orcutt, Xavier and Chen, Kan and Mamtani, Ronac and Long, Qi and Parikh, Ravi B},
title = {Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {2},
pages = {457--465},
doi = {10.1038/s41591-024-03352-5}
}
EUVIMED